Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02277743 · ClinicalTrials.gov registry record · Phase 3
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study of Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 671
- Enrollment target
- 20
- Study locations
NCT02277743 is a Phase 3 study of Dermatitis, Atopic that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 671 participants, above the 374-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT02277743, a Phase 3 study of Dermatitis, Atopic, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 671 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG Dupilumab
- DRUG Placebo (for Dupilumab)
Study Locations (20)
California
- - Clovis
- - Lomita
- - Los Angeles
- - Oceanside
- - Palmdale
- - Rolling Hills Estates
- - San Diego
- - Santa Monica
- - Stockton
Florida
- - Boca Raton
- - Clearwater
- - Fort Lauderdale
- - Miami
- - Miami Lakes
- - Pensacola
- - Tampa
Arkansas
- - Fort Smith
- - Rogers
Alabama
- - Birmingham
Georgia
- - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02277743
The ClinicalTrials.gov registry entry for NCT02277743 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 671 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 374-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (79% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which Dupilumab is the first listed.
NCT02277743 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02277743 about?
NCT02277743 is a clinical study titled "Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis". This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT02277743?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 671 participants. The study started on 2014-10. Estimated completion is 2016-02.
What conditions does trial NCT02277743 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT02277743?
The interventions under investigation include: Dupilumab (DRUG), Placebo (for Dupilumab) (DRUG).
Who is sponsoring clinical trial NCT02277743?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02277743 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
-
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
COMPLETED · Phase 3
-
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
COMPLETED · Phase 3
-
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.